In this study we seek to evaluate the value of tetrachlorodecaoxygen as an intra and postoperative adjuvant in the surgical management of primarily closed tibial fractures fixed with plate and screws. We reasoned that its prophagocytic and antiinflammation properties should decrease acute inflammation and associated complications. Of 41 cases of tibial fractures included in the study, seven were grade III open fractures. No adverse effects were observed from the use of tetrachlorodecaoxygen. There was no occurrence of acute compartment syndromes or chronic deep tissue infections. All subjects were able to bear weight within 16 to 24 weeks. We concluded that the use of tetrachlorodecaoxygen is of benefit when used as an adjuvant in the primary fixation and wound closure of tibial fractures.
INTRODUCTION
. Grade III fractures are further graded based on the ability to cover the defect (IIIA, defect amenable to closure; IIIB, defect not amenable to closure; and, IIIC presence of neurovascular injury) 4 .
One management option for tibial fractures is primary plate and screw fixation, but it has been associated with acute and/or chronic inflammation attributed to the extensive softtissue damage resulting from the surgical procedure, in addition to the initial damage caused by the trauma [5] [6] [7] [8] . Tetrachlorodecaoxygen may help to decrease inflammation and associated complications stemming from plate and screw fixation. It is an agent that is currently used to attenuate inflammation in transplantation patients, and patients with chronic inflammation due to immunosuppression. This agent is capable of promoting local immunity while at the same time restricting inflammation by augmenting phagocytic activity of macrophages and suppressing macrophage ability to recruit other inflammatory cells by interfering with its antigen presenting activity 9, 10 . A prototype of tetrachlorodecaoxygen, WF10, has been shown to be safe and has had promising results when used as an adjuvant in a systemic therapy against transplant rejection and chronic infection associated with immunocompromised patients [11] [12] [13] [14] . In the present study, we evaluated the use of tetrachlorodecaoxygen, for cleaning and irrigating tibial fractures managed with primary plate fixation, including open fracture cases where wounds are primarily closed. Tetrachlorodecaoxygen (Oxoferin®, 0.002% in 30 ml, manufactured by Pharos, Indonesia) was used for all patients in this study. For closed fractures and open grade I and II fractures, tetrachlorodecaoxygen solution was used intraoperatively to soak the plate, screws and wound prior to implant insertion and immediately prior to wound closure ( Figure 1 ). For open grade IIIA and B fractures, the solution was also used as a once a day 2.5-5 cc wound irrigatant through a Penrose drain for three to five days post surgery ( Figure 2 ). For fixation, we used 8 hole, 4.5 mm narrow plates (Figure 1 ), approximately 13.5 mm in length, 12.0 mm wide, and 3.6 mm thick (manufactured by Martin, Germany). We observed neither extensive inflammation nor sign of impending compartment syndrome in any of the study subjects. There were also no cases of either superficial or deep wound infection. All cases were partially or fully weight bearing within 16 to 24 weeks postoperatively with a median of 20 weeks. Radiographically, all cases showed complete bony union at 16-28 weeks after surgery, with a median of 20 weeks. No significant loosening or septic pseudoarthrosis was observed in any of the cases.
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The choice of management for tibial fractures depends on the types and degree of the fracture, but also on surgeon preference. Internal fixation with plate and screws for tibial fracture has fallen out of preference due to the high degree of tissue damage and associated infection resulting from the surgical procedure. Due to its relatively low cost, however, plate and screw fixation is still widely used for tibial fracture in this country.
Traditionally, wounds associated with open fractures, especially with grade III fractures are not closed after initial wound debridement. Recent studies have shown the advantages of primarily closing such wounds, and reported a comparable complication rate to delayed closure 15, 16 . Intraoperative use of tetrachlorodecaoxygen solution for the treatment of closed and type I/II open fractures with primary closure of wounds did not result in a higher rate of complications. Twenty-seven closed cases and seven open cases healed with average time of 20 weeks. There was no occurrence of compartment syndrome or implant associated infections in all cases, which compares favourably to our personal experience and published results with other methods. We hypothesized that the use of tetrachlorodecaoxygen solution may decrease inflammation resulting from damages to the tissue resulting from implant insertion procedure. The observational nature of our current study may not offer the best evidence for clinical practice. The majority of cases reported here were fractures of the tibial diaphysis. Further evaluation for metaphyseal or intra articular fractures may be necessary.
CONCLUSION
The use of tetrachlorodecaoxygen solution as an adjuvant to primary plate fixation and wound closure of a tibial fracture may be beneficial due to its anti-inflammatory and effect. The solution can be used for closed and selected open tibial fractures treated with primary plate fixation.
